Hurma sarms LGD-4033 Ligandrol
Nutrobal (Mk-677), (MK-2866), GW-501516 (Cardarine) , RAD140 （Testolone, Radarine, LGD-4033 (Ligandrol, Anabolicum) , DPT130, YK-11, SR9009 (Stenabolic， MELT), Andarine (S-4), Aicar
Name: LGD-4033Â
Synonyms:LGD-4033, Ligandrol, VK5211
CAS: 1165910-22-4
Brand:Hurma
Solubility: Propylene Glycol, DMSO, Ethanol
Molar Mass: 338.25 g/mol
Chemical Formula: C14H12F6N2O
Storage: Room temperature
Melting point: 105 - 106 °C
Organoleptic Profile: White fine powder, odorless, tasteless
sical Form: Solid, powder
What Are The Benefits of LGD-4033?
LGD-4033 is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Usages of LGD-4033
Ligandrol is a selective androgen receptor modulator (SARM) that is popular among bodybuilders and athletes for both bulking and cutting. At doses of 10mg per day, the supplement has been shown to lead to 5 to 10 pounds of lean mass gains every month.In the bodybuilding and athletic worlds, Ligandrol is used as a side-effect free alternative to steroids.
Although Ligandrol can be used for both bulking and cutting, it appears to be more popular for bulking. There are stories of nomenal weight gain progress while taking Ligandrol. As you’ll learn in the next section about quarterback Will Grier, sometimes these weight gains can be so significant that they arouse suspicion.
LGD-4033 is relatively strong compared to similar products. It has an / androgenic ratio of approximately 10:1. To put that ratio in perspective, ’s ratio is 1:1. Some sources also claim that Ligandrol is 11 times stronger than its popular competitor, .
